HISTORY OF THE SMITH-LEMLI-OPITZ SYNDROME Fifty years ago, the Smith-Lemli-Opitz Syndrome (SLOS) was described in three male patients by pediatricians David W Smith, Luc Lemli and John Opitz at the University of Wisconsin, USA, for the first time. 1 It was designed as a clinical description of all patients who had microcephaly and hypogenitalism.
SLOS was initially named RSH, a non-descriptive acronym of the first letters of the original patients' surnames. Its name was later changed in order to honor the three geneticists who first described this disorder. Soon after, it was usual practice to distinguish between a less-expressed form of SLOS, named type I, and the more severe type II form. Since the findings of the molecular cause of SLOS, it is clear that the subdivision into these two forms is inappropriate. The difference between type I and type II SLOS can be explained as a consequence of the underlying mutations.
Just 30 years later, Tint et al 2 published their measurements of neutral sterols in the plasma of five patients with SLOS and found abnormally low concentrations of cholesterol, but greater than 1000-fold increases in the level of 7-dehydrocholesterol, the immediate precursor of cholesterol in the Kandutsch-Russell pathway for biosynthesis of cholesterol. This step in the biosynthesis of cholesterol is catalyzed by D7-dehydrocholesterol reductase. Subsequently, the underlying DHCR7 gene was identified and cloned in 1998. 3 CLINICAL PHENOTYPE AND VARIABILITY Typical symptoms of SLOS include 2, 3 toe syndactyly and facial dysmorphisms as, for example, anteverted nares, which are key features of these patients. The characteristic craniofacial appearance of SLOS patients is independent from the clinical or biochemical severity. 4 Even the least-affected patients may show a characteristic facial phenotype. Individuals with SLOS have a number of neurodevelopmental problems, which are a consistent part of the syndrome. The most commonly observed brain abnormalities affect midline structures, such as the corpus callosum, intraventricular septum, and interior cerebellar vermis, 5 and, if present, may contribute to the neurodevelopmental symptoms.
The disease phenotype in SLOS is mainly thought to be caused by a lack of cholesterol and accumulation of 7-and 8-DHC (dehydrocholesterol) during embryogenesis. 2 But as the biochemical pathogenesis is still incompletely understood, no proven therapy for this disease exists to date.
Roullet et al 6 hypothesized that accumulation of cholesterol precursors might lead to a preference for other additional sterol pathways. They showed that SLOS patients exhibit an altered urinary excretion of 3-methylglutaconic acid (3MGC) and a diversion of the sterol precursor farnesyl-PP toward long-chain isoprenoids. No evidence for mevalonate shunting was demonstrated in moderately affected SLOS patients. On the other hand, significant pathophysiology regarding SLOS phenotype occurs in the brain of SLOS patients, which might be explained by the various distribution patterns of cholesterol, 7-DHC and DHCOE (oxysterol metabolite of 7-DHC) in the brain regions. 7 By comparing the SLOS patients' clinically described severity scores 8 along with the corresponding biochemical data and their genotypes, a clear correlation between genotypes and phenotypes 9 became evident. This correlation was confirmed in Polish patients. 10 However, SLOS patients with the same genotype did show a wide range in phenotype and clinical severity. This led to the assumption that additional modifying factors, apart from the DHCR7 genotype, influence the SLOS phenotype and disease severity. A surprising finding in SLOS was the modifying effect of apoE on the clinical severity of the disease. It was shown that disease severity varies significantly depending on whether the apoE alleles e2, e3 or e4 were carried by the respective patient's mother 11 (Figure 1 ). Another possible modifier of severity might be ABCA1. 12 
SPECTRUM OF DHCR7 MUTATIONS IN SLOS PATIENTS
As discussed, SLOS is a metabolic and malformation disorder caused by mutations in the DHCR7 gene (7-dehydrocholesterol reductase, reference sequences: NG_012655, NM_001360.2, LRG_340) on chromosome 11. The first pathogenic mutations in SLOS patients were detected by our group in Innsbruck, Austria, as well as by the groups of Wassif and of Waterham in 1998. [13] [14] [15] So far, more than 130 disease-causing mutations have been described and all reported patients in the literature are included in a DHCR7 database (http:// databases.lovd.nl/shared/genes/DHCR7). The interpretation of newly detected variants, genotypes and phenotypic severity is more accurately possible using such well-defined databases.
Despite the fact that a large number of mutations have been identified, the majority of the SLOS cases are caused by the five most abundant mutations. The most common mutation is the splice site mutation c.964-1G4C (transcript reference sequence: NM_001360.2, frequency of 29% in SLOS alleles), 9 
SLOS THERAPIES
The basic therapeutic approach to SLOS is treatment by cholesterol substitution. It has been suggested that adding HMG-CoA reductase inhibitors like simvastatin might lessen the disease severity 17 because simvastatin can cross the blood-brain barrier. The principal problem of the disease is that the clinical phenotype is due to lack of cholesterol during embryogenesis; hence therapy would be needed at that moment.
New therapeutic approaches aim to inhibit the formation of the toxic precursor 7-DHC or 7-DHC-derived oxysterols by antioxidant supplementation. Antioxidants, specifically vitamin E supplementation, can effectively inhibit the peroxidation of 7-DHC in SLOS fibroblasts and newborn Dhcr7-KO mice. 18 Fifty years after the first description of SLOS the molecular base seems to be well established, whereas the clinical and biochemical pathophysiology behind the disease is less clear, as cholesterol serves various complicated functions in metabolism. In order to achieve constructive therapies for SLOS patients, it is necessary to continue research on this metabolic malformation syndrome. 
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